Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Protagonist Therapeutics Inc (PTGX) USD0.00001

Sell:$10.67 Buy:$10.68 Change: $0.13 (1.16%)
NASDAQ:0.73%
Market closed |  Prices as at close on 15 November 2019 | Switch to live prices |
Sell:$10.67
Buy:$10.68
Change: $0.13 (1.16%)
Market closed |  Prices as at close on 15 November 2019 | Switch to live prices |
Sell:$10.67
Buy:$10.68
Change: $0.13 (1.16%)
Market closed |  Prices as at close on 15 November 2019 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company with a peptide technology platform focused on discovering and developing new chemical entities (NECs) to address significant unmet medical needs. The Company's product pipeline includes PTG-100, PTG-200 and PTG-300. Its primary focus is on developing oral peptide drugs that target biological pathways also targeted by marketed injectable antibody drugs. PTG-100 is an oral, alpha-4-beta-7 (a4b7) integrin-specific antagonist peptide product candidate, which has completed a Phase I clinical trial in normal healthy volunteers (NHVs). PTG-100 is being developed for treatment of moderate-to-severe ulcerative colitis (UC). PTG-200 is an oral Interleukin-23 receptor (IL-23R) antagonist being developed for moderate-to-severe Crohn's disease (CD). PTG-200 is in investigational new drug (IND) enabling studies. PTG-300 is an injectable hepcidin mimetic for treatment of iron overload related rare diseases.

Contact details

Address:
7707 Gateway Blvd Ste 140
NEWARK
94560-1160
United States
Telephone:
+1 (510) 4740170
Website:
www.protagonist-inc.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
PTGX
ISIN:
US74366E1029
Market cap:
$282.13 million
Shares in issue:
27.21 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Harold Selick
    Independent Chairman of the Board
  • Dinesh Patel
    President, Chief Executive Officer, Director
  • Donald Kalkofen
    Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer
  • David Liu
    Chief Scientific Officer, Head of Research & Development
  • Suneel Gupta
    Chief Development Officer
  • Samuel Saks
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.